Health & Policy | August 2026 | 4 min read
Quick Takeaways
- The FDA has approved Mounjaro for cardiovascular risk reduction in adults with type 2 diabetes.
- The label now covers risk reduction for cardiovascular death, non-fatal heart attack and non-fatal stroke.
- Approval was supported by SURPASS-CVOT, a head-to-head trial against Trulicity.
- Mounjaro showed an 8% lower rate of major cardiovascular events versus Trulicity.
- The trial found no major new safety concerns, with stomach-related side effects most common.
The FDA’s latest approval expands Mounjaro’s role beyond blood sugar control, adding cardiovascular risk reduction for high-risk adults with type 2 diabetes.
| 13,000+ Patients | 30 Countries | 8% Lower Rate |
| SURPASS-CVOT enrolment | Trial footprint | MACE-3 vs Trulicity |
FDA Expands Mounjaro Approval
The U.S. Food and Drug Administration has approved Eli Lilly’s Mounjaro, also known as tirzepatide, to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for those events. The new approval covers cardiovascular death, non-fatal heart attack and non-fatal stroke.
Mounjaro was already used to improve blood sugar control in people with type 2 diabetes. The expanded approval means the drug can now also be used for a major heart-risk indication in eligible adults. This is important because heart disease remains a leading cause of death among people living with type 2 diabetes.
| Patient Context: This is not a general approval for everyone with diabetes. The cardiovascular indication applies to adults with type 2 diabetes who are at high risk for these events. |
SURPASS-CVOT Compared Mounjaro With Trulicity
The decision was supported by results from SURPASS-CVOT, a large cardiovascular outcomes trial that compared Mounjaro directly with Trulicity, Lilly’s older GLP-1 medicine dulaglutide. Unlike many cardiovascular trials that test a medicine against placebo, this study compared two incretin-based therapies head to head.
The trial enrolled more than 13,000 patients across 30 countries and followed them for more than four and a half years. Mounjaro demonstrated non-inferiority to Trulicity and showed an 8% lower rate of cardiovascular death, heart attack or stroke. However, Lilly’s own clinical information notes that superiority was not established.
| Area | Mounjaro Update | Why It Matters | Status |
| FDA approval | Expanded cardiovascular indication | Adds heart-risk reduction use | Approved |
| Population | Adults with type 2 diabetes at high CV risk | Targets higher-risk patients | Defined |
| Trial | SURPASS-CVOT | Compared Mounjaro with Trulicity | Completed |
| Main measure | CV death, heart attack or stroke | Tracks serious heart outcomes | Measured |
| Result | 8% lower MACE-3 rate vs Trulicity | Supports expanded label | Reported |
| Safety | No major new concerns identified | Consistent with prior studies | Monitored |
What Patients Should Know About Safety
Lilly said the study did not identify major new safety concerns. The safety profile was broadly in line with previous Mounjaro studies. Gastrointestinal problems remained the most commonly reported side effects, and most were described as mild to moderate.
Patients should still use Mounjaro only under medical supervision. Doctors consider a patient’s diabetes control, cardiovascular risk, other medicines, side-effect history and overall health before choosing treatment. People should not start, stop or switch diabetes medicines without advice from a qualified healthcare professional.
| Safety Note: The 8% figure compares Mounjaro with Trulicity in the trial. It should not be read as a guaranteed individual risk reduction for every patient. |
Why the Approval Matters for Diabetes Care
The approval strengthens the shift toward diabetes medicines that address more than blood sugar. For many patients with type 2 diabetes, the most serious long-term risks include heart attack, stroke and cardiovascular death. A drug label that includes cardiovascular risk reduction can influence how clinicians think about treatment for higher-risk adults.
Lilly says Mounjaro is the first and only medicine to target both GIP and GLP-1 receptors and reduce cardiovascular risk in this patient group. The next phase will depend on access, doctor prescribing decisions, insurance coverage and how the medicine fits into broader diabetes and heart-health care plans.
| Care Reminder: People with type 2 diabetes and heart-risk concerns should discuss personalised treatment options with their doctor rather than relying on headlines alone. |
Disclaimer: This article is for general information only and is not medical advice. Patients should consult a licensed healthcare professional before making any treatment decision.
